HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
These findings establish the first human safety and pharmacokinetic profile of a novel, orally administered actinide chelator and support further clinical evaluation of HOPO 14-1 as a countermeasure for internal radionuclide and heavy metal contamination.
Appeared: Friday, November 13. JAMA. Peer-reviewed journal.